BiotechTube

DS-5565

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pain Associated With Fibromyalgia

Conditions

Pain Associated With Fibromyalgia

Trial Timeline

Feb 4, 2015 → Apr 19, 2017

NCT ID
NCT02234583

About DS-5565

DS-5565 is a phase 3 stage product being developed by Daiichi Sankyo for Pain Associated With Fibromyalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT02234583. Target conditions include Pain Associated With Fibromyalgia.

What happened to similar drugs?

20 of 20 similar drugs in Pain Associated With Fibromyalgia were approved

Approved (20) Terminated (4) Active (0)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅0.75% bupivacaine + .75% bupivacaine + .75% bupivacaineSI-BONEApproved
✅pregabalin sustained release tablet + pregabalin immediate release capsuleYuhanApproved
✅Topical High dose Capsaicin + Topical PlaceboAstellas PharmaApproved
✅Solifenacin succinate treatment + Oxycodone and acetaminophen combination treatmentAstellas PharmaApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅Duloxetine + Pregabalin + PlaceboShionogiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02607280Phase 3Completed
NCT02234583Phase 3Completed

Competing Products

20 competing products in Pain Associated With Fibromyalgia

See all competitors
ProductCompanyStageHype Score
DFN-15 (Celecoxib Oral Solution) 62.5 mg + DFN-15 (Celecoxib Oral Solution) 125 mg + DFN-15 (Celecoxib Oral Solution) 250 mg + PlaceboDr. Reddy's LaboratoriesPhase 2
32
PRF110- oily solution (Ropivacaine)PainReformPhase 2
25
PRF110PainReformPhase 2
21
PRF-108 + Placebo + Ropivacaine + PRF-110PainReformPhase 1/2
22
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
19
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
TRV130TrevenaPhase 3
30
TRV130 + Morphine + PlaceboTrevenaPhase 2
25
TRV130TrevenaPhase 2
17
LY3556050 + PlaceboEli LillyPhase 2
35
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Nanoformed Piroxicam IR Tablet + Felden (piroxicam) Tablets + Brexidol (piroxicam) TabletsNanoform FinlandPhase 1
23
0.75% bupivacaine + .75% bupivacaine + .75% bupivacaineSI-BONEApproved
29
LY3526318 + PlaceboEli LillyPhase 2
35
LY3857210 + PlaceboEli LillyPhase 2
35
OK-101 0.05% + OK-101 0.1% + PlaceboOKYO PharmaPhase 2
17
YHD1119 + LyricaYuhanPhase 1
29
YHD1119 + LyricaYuhanPhase 1
29
YHD1119 + LyricaYuhanPhase 3
40